Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

2020/03/20 by Ghassan K Abou-Alfa, Ghassan K. Abou‐Alfa, Vaibhav Sahai +26 · 14 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cholangiocarcinoma and Gallbladder Cancer Studies #Fibroblast Growth Factor Research #IgG4-Related and Inflammatory Diseases

paper · doi:10.1016/s1470-2045(20)30109-1

openalex publication_date 2020/03/20 · crossref created 2020/03/20 · crossref issued 2020/05/01 · crossref published 2020/05/01 · crossref published-print 2020/05/01 · openalex created_date 2025/10/10 · crossref deposited 2025/10/26 · crossref indexed 2026/07/26 · openalex updated_date 2026/08/04

Citations

• THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
• Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Cited by

• KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
• Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers
• Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
• Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges
• NUF2 and NEK2 promote malignant progression of gallbladder cancer by remodeling the extracellular matrix
• Tumour-agnostic kinase inhibitors
• Long-term outcomes in patients with advanced intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy
• Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma
• New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
• Gastrointestinal cancer: molecular pathogenesis and targeted therapy
• Neoadjuvant pemigatinib as a bridge to living donor liver transplantation for intrahepatic cholangiocarcinoma with FGFR2 gene rearrangement
• Automated imaging workflow for FISH-stained tissue microarrays enables assessment of FGFR2 translocations in a large intrahepatic cholangiocarcinoma patient cohort
• Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer
• FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH